Genmab Reaches Analyst Target Price
May 19, 2020 at 08:11 AM EDT
In recent trading, shares of Genmab A/S (GMAB) have crossed above the average analyst 12-month target price of $29.25, changing hands for $29.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..